Skip to main content
. 2017 Nov 9;1(24):2247–2256. doi: 10.1182/bloodadvances.2017010686

Figure 3.

Figure 3.

Major outcomes after HCT for patients with newly diagnosed stage 3 disease according to the R-ISS, n = 14. Cumulative incidence frequencies of NRM (A) and myeloma relapse or progression (B). Kaplan-Meier estimates of PFS (C) and OS (D). All outcomes shown are based on intention to treat and counted from the time of autoHCT.